Cladribine in indolent non-Hodgkin's lymphoma

Expert Review of Anticancer Therapy
Darren S Sigal, Alan Saven

Abstract

Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells, making it highly active in indolent lymphoproliferative diseases. In clinical practice, cladribine is mostly used in the treatment of hairy cell leukemia and Waldenström's macroglobulinemia. However, its remarkable activity in follicular lymphoma and other indolent non-Hodgkin's lymphoma subtypes has not been more widely appreciated. Cladribine compares favorably to other standard treatments for these conditions. Future Phase III clinical studies should incorporate cladribine into multiagent chemotherapy programs to more fully evaluate its potential in indolent non-Hodgkin's lymphoma.

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonJ E Seegmiller
Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·A CohenD W Martin
Mar 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M SantanaR L Blakley
Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C KayL D Piro
Oct 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J LiliemarkG Juliusson
Oct 17, 1992·Lancet·E Beutler
May 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R RedmanM J Keating
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S HochsterM J O'Connell
Feb 1, 1985·The Journal of Clinical Investigation·S SetoD A Carson
Jun 1, 1986·Experimental Cell Research·D A CarsonC J Carrera
Jun 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Z EzdinliM J O'Connell
Feb 7, 1980·Nature·B W DurkaczS Shall
Nov 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonJ A Montgomery
Dec 6, 1984·The New England Journal of Medicine·S J Horning, S A Rosenberg
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D A CarsonE Beutler
Nov 1, 1995·Arthritis and Rheumatism·B EibschutzD A Carson
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A I Richards
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HoffmanK Rai
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosR Alexanian
Feb 1, 1993·Annals of Internal Medicine·M A DimopoulosR Alexanian
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL D Piro
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A LarsonM J Ratain
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Solal-CélignyM Leporrier
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SavenL Piro
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G JuliussonJ Liliemark
Oct 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D C BetticherT Cerny
Jan 1, 1997·Leukemia & Lymphoma·V A CanfieldC Nichols
May 7, 1998·Leukemia & Lymphoma·G NadaliG Pizzolo
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·L M LeoniD A Carson
Aug 26, 1998·Leukemia & Lymphoma·J LiliemarkG Juliusson
Dec 19, 1998·British Journal of Haematology·E S LiuA Saven
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A FridrikW Linkesch
Mar 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J RummelP S Mitrou
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonB Freidlin
Apr 13, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C TondiniG Bonadonna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.